Liu et al find that mesothelin (MSLN), a candidate target for antibody-based cancer therapy, is targeted by several proteases, and that inhibition of shedding facilitates killing of cells by an immunotoxin targeting MSLN. This evidence concerns the gene MSLN and cancer.